November 12, 2023

New clinical data on Rayaldee (ER calcifediol) presented at Kidney Week 2023 – OPKO Health Inc

OPKO Health, Inc. presented late-breaking clinical data on Rayaldee extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia. These data, presented in a poster titled “Control of Secondary Hyperparathyroidism with Extended-release Calcifediol is Associated with Slower CKD Progression” (#TH-PO1152), indicate that early, sustained and effective treatment of secondary hyperparathyroidism (SHPT) with Rayaldee is associated with […]

admin Health 0 1 min read
March 9, 2022

EU approves Ngenla in growth hormone deficient children – Pfizer + OPKO Health

Pfizer and OPKO Health announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone Ngenla (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. Ngenla provides pediatric patients, their caregivers and healthcare providers with a new treatment option […]

admin Health 0 39 sec read

Recent Posts

Meta

Categories

Archives

Recent Comments